biosimilar portfolio
Scope
Date
~
-
Bio & Pharma
Celltrion Healthcare to supply Yuflyma to five regional gov’ts in Italy
South Korea's Celltrion Healthcare Co. announced on Monday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatm...
Sep 18, 2023 (Gmt+09:00)
-
KOREA Investment Week 2023
Celltrion builds clinical data bank for new biosimilars
The use of data and computing is a new paradigm in the biopharmaceutical industry, reducing the new drug development time and cost, Celltrion Inc. C...
Sep 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis to cooperate with Swiss firm Sandoz
Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, announced on Monday that it signed a partn...
Sep 11, 2023 (Gmt+09:00)
-
Artificial intelligence
S.Korea's KT invests in domestic startups Upstage, Qanda
South Korea's KT Corp. has invested 20 billion won ($15 million) in two domestic artificial intelligence (AI) startups. For the second time in ...
Sep 11, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to release Stelara biosimilar in US from March 2025
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it has completed a patent agreement with Johnson & Johnson, the m...
Aug 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets OK partial approval for phase 3 of biosimilar in Europe
South Korean biopharmaceutical company Celltrion Inc. announced on Tuesday that it has received approval from the European Medicines Agency (EMA) fo...
Aug 22, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis seeks to buy Biogen biosimilar unit
Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea’s Samsung Group, seeks to buy a biosimilar business d...
Aug 02, 2023 (Gmt+09:00)
-
Fashion
S.Korea’s fashion brand Handsome expands overseas portfolio
South Korean fashion company Handsome Corp. is accelerating expansion of its portfolio for licensing foreign brands.The company on Monday said it co...
Jul 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis enters US market for biosimilars of Humira
South Korea's biopharmaceutical company Samsung Bioepis, which was expected to struggle on the US market for biosimilars of Humira, the world's top-...
Jul 14, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches Humira biosimilar Yuflyma in US
South Korean biopharmaceutical company Celltrion Healthcare on Monday said it launched the day before on the US market Yuflyma, a biosimilar of the ...
Jul 04, 2023 (Gmt+09:00)
-
Business & Politics
Samyang Foods Group rebrands as Samyang Roundsquare
South Korea's food-oriented Samyang Foods Group said on Monday it rebranded the group and the holding company Samyang Naturals Co.'s name as Samyang...
Jul 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in US for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...
Jun 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion puts Takeda’s assets up for sale after 3 years
South Korea’s Celltrion Inc. has put its Japanese Takeda Pharmaceutical Co.'s primary care assets acquired in 2020 on sale as the biosimilar g...
Jun 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US
South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA...
Jun 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand biosimilar portfolio to 11 by 2025
South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it plans to beef up its portfolio by applying for regulatory approv...
Jun 13, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis to enhance biosimilar presence with Epysqli
FRANKFURT – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is looking to gain ground in the ra...
Jun 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to develop Humira biosimilar oral medication with US firm
South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...
Jun 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Remsima SC praised in Europe as preferred biosimilar
MILAN – South Korea's biopharmaceutical company Celltrion Inc. is known in Europe for its biosimilar products such as autoimmune disease treat...
Jun 02, 2023 (Gmt+09:00)
-
Venture capital
SK Networks eyes partnership with US-based Bow Capital
SK Networks Co., a South Korean trading company, is seeking to form a partnership with Silicon Valley-based venture capital firm Bow Capital to dive...
May 31, 2023 (Gmt+09:00)
-
Korean stock market
Funds with high exposure to Nvidia, Samsung yield higher returns
It's time again to snap up semiconductor stocks – the market darlings these days.Just like its global peers, including the New York Stock Exch...
May 31, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion unveils phase 1 clinical data of Actemra biosimilar in Europe
South Korean biosimilar giant Celltrion Inc. revealed on Wednesday the highly anticipated clinical phase 1 data for its Actemra biosimilar, CT-P47, ...
May 31, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis gets approval to sell biosimilar in Europe
South Korea's Samsung Bioepis has received approval in Europe to sell a biosimilar of Soliris, a drug for the treatment of adult and children patien...
May 31, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets FDA approval for Humira biosimilar CT-P17
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...
May 24, 2023 (Gmt+09:00)
-
Retail
MLB apparel by Korea's F&F finds favor in China
F&F Co., a South Korean outdoor fashion retailer, has notched a success selling US Major League Baseball (MLB) apparel in China. This comes desp...
May 21, 2023 (Gmt+09:00)
-
ASK 2023
Secondaries, debt attractive for portfolio stability: Korean CIOs
South Korean institutional investors find secondaries and private debt attractive amid the darkening economic outlook, chief investment officers (CI...
May 17, 2023 (Gmt+09:00)
-
Batteries
LG Chem aims higher for battery materials with diverse portfolio
South Korea’s LG Chem Ltd. on Tuesday revised up its 2030 sales goal for battery materials by 45% after it delivered stronger-than-expected re...
May 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for Phase 3 clinical trials in Europe for biosimilar
South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...
May 03, 2023 (Gmt+09:00)
-
Korean stock market
Super-rich Koreans eye return to stocks despite weaker economy
The super-rich in South Korea are eyeing stocks for investments despite a slowdown in Asia’s fourth-largest economy this year, expecting the l...
Apr 10, 2023 (Gmt+09:00)
-
Batteries
LS Electric wins order $94 mn for energy storage system in UK
LS Electric Co. announced on Tuesday that it has secured a contract for a £73.6 million ($93.5 million) energy storage system (ESS) project in...
Apr 04, 2023 (Gmt+09:00)
-
Insurance
Hanwha Life acquires Indonesia's Lippo General Insurance
South Korea's Hanwha Life Insurance said on Thursday that it has acquired a 62.6% stake in Indonesian insurer Lippo General Insurance, in collaborat...
Mar 30, 2023 (Gmt+09:00)